Solidseq Lung Cancer Panel [72 Genes] Test
About Solidseq Lung Cancer Panel [72 Genes] Test
| Field | Value |
|---|---|
| Also Known As | Solidseq Lung Cancer 72-Gene Panel, Lung Cancer Comprehensive NGS Panel, Somatic Tumour Profiling Panel |
| Sample Type | FFPE Tissue Block (formalin-fixed, paraffin-embedded tumour tissue) |
| Fasting Required | No |
| Report Time | 30 days |
| Recommended For | Adults of all genders diagnosed with non-small cell lung cancer (NSCLC), particularly advanced or metastatic disease |
| Price | Starting at ₹36,000 |
What Is a Solidseq Lung Cancer Panel [72 Genes] Test?
The Solidseq lung cancer panel [72 genes] test is a specialised genetic test that analyses tumour tissue for mutations across 72 cancer-related genes. It uses Next-Generation Sequencing (NGS), a technology that reads large stretches of DNA quickly and accurately. Oncologists use this test to identify the specific genetic changes driving a patient's lung cancer and to guide targeted treatment decisions. It is also known as the Solidseq lung cancer 72-gene panel, the lung cancer comprehensive NGS panel, or the somatic tumour profiling panel.
What Does a Solidseq Lung Cancer Panel [72 Genes] Test Measure?
This panel scans tumour tissue DNA for four types of genetic alterations: single nucleotide variants (point mutations), insertions or deletions of small DNA sequences, gene fusions (where two genes join abnormally), and copy number variations (abnormal gene copies). The genes are grouped below by their role in cancer biology:
| Category | Genes Tested | Why It Is Tested |
|---|---|---|
| Receptor Tyrosine Kinases | EGFR, ALK, ROS1, RET, MET, ERBB2, ERBB3, ERBB4, KIT, PDGFRA, PDGFRB, FLT3, FLT4, KDR, NTRK1, NTRK2, NTRK3, DDR2, AXL | Identify actionable mutations for targeted therapy |
| RAS/RAF/MAPK Signalling | KRAS, NRAS, HRAS, BRAF, ARAF, RAF1, MAP2K1, MAP2K2, MAPK1, RIT1, SOS1 | Predict response to MEK or BRAF inhibitors; detect EGFR therapy resistance |
| PI3K/AKT/mTOR Pathway | PIK3CA, PIK3CB, PIK3CD, PIK3CG, PIK3C2B, PIK3R2, AKT1, AKT2, AKT3, MTOR, RICTOR, RHEB | Assess signalling pathways that control cell growth and survival |
| Cell Cycle Regulators | CDK4, CDK6, CCND1, CCND2, CCND3, CCNE1, E2F1, MDM4 | Evaluate cell division control and CDK inhibitor eligibility |
| Transcription Factors and Regulators | MYC, MYCN, SOX2, MYOD1, FOXA1, FOXL2, FOXO1, GATA2, NFE2L2, EZH2, KLF4, KLF5, STAT3, STAT5B, STAT6, MECOM, MEF2B, IRF4 | Understand how gene expression is altered in tumour development |
| Apoptosis and Cell Survival | BCL2, BCL2L12, BCL6 | Assess resistance to programmed cell death |
| G-Protein Signalling | GNA11, GNAQ, GNAS, CYSLTR2 | Identify alterations in downstream signalling cascades |
| Epigenetic Regulators | IDH1, IDH2, H3F3A, H3F3B, HIST1H2BD, HIST1H3B, SETBP1, CHD4 | Evaluate chromatin modifications that affect gene expression |
| Kinase Signalling and Other Oncogenes | ABL1, ABL2, BTK, CSF1R, SRC, AURKA, AURKC, PIM1, TERT | Assess additional druggable targets and prognostic markers |
| Splicing and RNA Processing | SF3B1, SRSF2, U2AF1, DROSHA, DGCR8, MAGOH, PCBP1 | Evaluate RNA processing alterations in tumour cells |
| TGF-beta/BMP Pathway | ACVR1, BMP5, TGFBR1 | Assess growth factor signalling |
| Wnt/Beta-catenin Pathway | CTNNB1, CUL1 | Evaluate developmental signalling pathway activity |
| Other Cancer-Associated Genes | AR, ESR1, SMO, GLI1, HIF1A, EPAS1, TOP1, XPO1, SPOP, RAC1, KNSTRN, PLCG1, PPP2R1A, PPP6C, PRKACA, PTPN11, PTPRD, IKBKB, CARD11, CD79B, MPL, MYD88, IL6ST, IL7R, PAX5, RARA, NSD2, NT5C2, RPL10, SIX1, SIX2, SLCO1B3, SMC1A, SNCAIP, TAF1, TPMT, TRRAP, TSHR, USP8, WAS, ZNF217, ZNF429, NUP93, RGS7, PXDNL, FAM135B, FGF7, MAX, FGFR1, FGFR2, FGFR3, FGFR4, CBL, EIF1AX | Various roles in tumour progression, therapy resistance, and emerging therapeutic targets |
Why Is a Solidseq Lung Cancer Panel [72 Genes] Test Done?
This test is ordered when an oncologist needs a detailed genetic picture of a patient's lung tumour to select the most appropriate treatment.
Common Symptoms That May Require This Test
A doctor may order this test after lung cancer has been confirmed in patients presenting with:
- Persistent cough that does not improve over weeks
- Unexplained weight loss
- Shortness of breath with minimal exertion
- Coughing up blood (haemoptysis)
- Chest pain or tightness
- Unusual fatigue
- Bone pain or fractures in cases where cancer has spread
Conditions This Test Can Help Detect
The Solidseq lung cancer panel [72 genes] test is used to assess the following conditions and scenarios:
- Non-small cell lung cancer (NSCLC), including adenocarcinoma, squamous cell carcinoma, and large cell carcinoma
- Identification of driver mutations (the primary genetic change fuelling cancer growth) for targeted therapy selection
- Detection of resistance mutations in patients whose cancer has progressed on prior therapy
- Assessment of eligibility for approved targeted therapies directed at EGFR, ALK, ROS1, BRAF, MET, RET, NTRK, ERBB2, and KRAS alterations
Solidseq Lung Cancer Panel [72 Genes] Test for Chronic Disease Monitoring
For patients already receiving targeted therapy, this panel can be repeated if the cancer stops responding to treatment. Repeat testing helps identify resistance mutations, such as the EGFR T790M variant that can emerge after first-generation EGFR inhibitor therapy. Results guide timely switches to alternative treatments and allow the oncology team to track how the tumour is evolving over the course of care.
How to Prepare and What to Expect
Because this test uses tumour tissue rather than a blood or urine sample, preparation is different from routine laboratory tests.
Do You Need to Fast?
No fasting is required. The sample is tumour tissue collected during a biopsy or surgical procedure, so dietary restrictions do not apply. Always follow specific instructions provided by your doctor.
Practical Tips Before Your Test
Here are a few things to arrange before submitting your sample:
- Bring a detailed clinical history, including your symptoms, previous test results, and family history, as this is required for the test
- Carry all previous biopsy blocks and pathology reports to the collection centre
- Inform the laboratory team of any prior chemotherapy or radiation treatment, as this may affect tissue quality
Step-by-Step Procedure
- Tumour tissue is collected by your treating physician via bronchoscopy, CT-guided needle biopsy, or surgical resection and preserved as an FFPE (formalin-fixed, paraffin-embedded) block.
- A pathologist reviews the FFPE block to confirm that it contains sufficient tumour cells, typically more than 10 to 20% tumour content.
- DNA and RNA are extracted from the tumour tissue in the laboratory.
- NGS library preparation is performed, and the extracted material is sequenced using next-generation sequencing technology.
- Bioinformatics software analyses the sequencing data to identify genetic variants across all 72 genes.
- Molecular pathologists interpret the findings and generate a detailed report, which is delivered within 30 days.
Factors That Can Affect Accuracy
Several pre-analytical factors can influence whether the test produces a valid result:
- Low tumour cell content in the tissue sample (less than 5% tumour cells increases the risk of test failure)
- Poor tissue fixation or incorrect formalin exposure time
- Age of the FFPE block (older blocks may contain degraded DNA)
- Sample site (bone biopsy specimens tend to yield lower sequencing success rates than lung tissue samples)
- Prior chemotherapy or radiation affecting DNA integrity in the tumour
Understanding Your Solidseq Lung Cancer Panel [72 Genes] Test Results
Results from this test are qualitative, meaning they report whether specific genetic alterations are present or absent rather than giving a numerical value. Your oncologist will interpret findings alongside your clinical history, histopathology results, and treatment history. The table below summarises key findings:
| Result Category | Interpretation |
|---|---|
| Pathogenic or Likely Pathogenic Variant Detected | A clinically significant alteration with established treatment implications has been identified |
| Variant of Uncertain Significance (VUS) | An alteration is detected but its clinical impact is currently unclear; correlation with clinical findings is needed |
| No Pathogenic Variants Detected | No known actionable mutations found in the 72 genes tested |
Disclaimer: These ranges are general guidelines. Your doctor will interpret your results based on your age, health history, and other factors. Always consult a qualified healthcare professional for personalised medical advice.
Results During Special Conditions
Prior targeted therapy can influence what mutations are detected. Patients who have received first-generation EGFR inhibitors may develop acquired resistance mutations such as EGFR T790M, which would appear on repeat testing. Co-occurring mutations in more than one driver gene (for example, EGFR alongside ALK or ROS1) are uncommon but do occur and can affect treatment decisions. Tumour heterogeneity may also mean that not all mutations present in the cancer are captured from a single biopsy site.
How to Maintain Healthy Levels
This is a cancer diagnostic test rather than a routine health screening. General guidance following testing includes:
- Work closely with your oncology team to understand your results and discuss treatment options
- Attend all follow-up appointments so your doctor can monitor treatment response
- Consider genetic counselling if a hereditary cancer predisposition is suspected based on your results or family history
Lupin Diagnostics Solidseq Lung Cancer Panel [72 Genes] Test Price
The Solidseq lung cancer panel [72 genes] test cost at Lupin Diagnostics starts at ₹36,000. This test requires a visit to a hospital; home collection is not available as it requires a tumour tissue block sample. The table below shows indicative prices:
| City | Approximate Price (₹) |
|---|---|
| BHOPAL | 36000 |
| CHENNAI | 36000 |
| HYDERABAD | 36000 |
| KOLKATA | 36000 |
| NAVI MUMBAI | 36000 |
| PUNE | 36000 |
Disclaimer: Prices are indicative and may vary by location. Please confirm the current price at the time of booking.
How to Book
- Select the test on the Lupin Diagnostics website.
- Choose your city and preferred centre location.
- Visit the centre at your scheduled time to submit your FFPE tissue block and clinical documents.
- Receive your report via email or WhatsApp within the stipulated turnaround time.
Frequently Asked Questions
The Solidseq lung cancer panel [72 genes] test is a specialised genetic test that uses NGS technology to examine 72 cancer-related genes in a tumour tissue sample. It identifies mutations, fusions, and other alterations that help oncologists choose the most suitable targeted therapy for each patient's specific cancer profile.
This test is recommended for patients diagnosed with non-small cell lung cancer (NSCLC), particularly those with advanced or metastatic disease. It is also suitable for patients whose cancer has stopped responding to current treatment and who require testing for resistance mutations to guide next-line therapy selection.
The sample is tumour tissue obtained through a biopsy, such as a bronchoscopy, CT-guided needle biopsy, or surgical resection. The tissue is preserved in an FFPE block and submitted to the laboratory.
At Lupin Diagnostics, the Solidseq lung cancer panel [72 genes] test has a turnaround time of 30 days. The report is delivered directly via email or WhatsApp.
If a targetable mutation is detected, for example in EGFR, ALK, ROS1, BRAF, RET, MET, or NTRK, your oncologist can consider a targeted therapy drug designed to block that specific alteration. Your doctor will discuss the most appropriate treatment plan based on the full result report.
Yes. If your cancer progresses during targeted therapy, repeat testing may reveal resistance mutations that explain why the current treatment has stopped working. This information helps your oncology team identify suitable next-line treatment options.
Yes. Clinical history is required for this test. Please bring a complete clinical history, including your diagnosis details, previous pathology reports, biopsy records, and details of any prior treatment, when submitting your sample at the Lupin Diagnostics centre.
Solidseq Lung Cancer Panel [72 Genes] Test
